Well-Funded Seres Races To Be First To Market With A Microbiome Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
After raising $143 million from an IPO in June, Seres Therapeutics is hoping its lead development candidate SER-109, in Phase II for Clostridium difficile, could be the first microbiome-based drug to reach the market.
You may also be interested in...
Seres Argues Different Diagnostic Needed In Recurrent C. Difficile Trials
As it talks study design with FDA, Seres says new analysis of Phase II trial of microbiome candidate SER-109 suggests that a C. difficile cytotoxin test would be more accurate and that a higher dose may be more effective.
Lilly's Tirzepatide Shows Up Novo's Ozempic In Head-To-Head Diabetes Trial
The dual GLP-1/GIP agonist outpaced Novo's blockbuster GLP-1 analogue at all three doses, including the important low dose, on A1C reduction and weight reduction in patients with type 2 diabetes.
Sanofi Paid $14.6bn In Rebates In 2020; Net Prices Were Down
The company released an annual pricing report, showing that Sanofi's US average net prices declined for the fifth year in a row.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: